Citations 2
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
LoRusso, Patricia , Krishnamurthi, S, Rinehart, John, Nabell, Lisle, Croghan, Gary A., Varterasian, Mary , Sadis, Seth, Menon, Sujatha, Leopold, Judith, Meyer, Mark B.
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3011-3011
Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients
Menon, Sujatha, Whitfield, Lloyd R., Sadis, Seth, Leopold, Judith, LoRusso, Patricia , Krishnamurthi, Smitha , Rinehart, John, Nabell, Lisle, Croghan, Gary A., Meyer, Mark B.
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3066-3066